Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-Co
- Tushar Savaliya
- Oct 4, 2021
- 6 min read
Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approach
Abstract
The SARS-CoV-2 pandemic has accelerated the study of existing drugs. The mixture of homologs called ivermectin (avermectin-B1a [HB1a] + avermectin-B1b [HB1b]) has shown antiviral activity against SARS-CoV-2 in vitro. However, there are few reports on the behavior of each homolog. We investigated the interaction of each homolog with promising targets of interest associated with SARS-CoV-2 infection from a biophysical and computational-chemistry perspective using docking and molecular dynamics. We observed a differential behavior for each homolog, with an affinity of HB1b for viral structures, and of HB1a for host structures considered. The induced disturbances were differential and influenced by the hydrophobicity of each homolog and the binding pockets. We present the first comparative analysis of the potential theoretical inhibitory effect of both avermectins on biomolecules associated with COVID-19 and suggest that ivermectin through its homologs, has a multiobjective behavior.

Introduction
SARS-CoV-2 is a novel virus belonging to the β-Coronavirus genus of the 2B group of the Coronaviridae family. This interesting virus contains only 29 proteins, 26 of which have been successfully expressed for in vitro studies to determine targets of interest for drug discovery [1]. For example, the conserved cysteine protease Mopar has been highlighted as an exciting target as it mediates the maturation cleavage of polyproteins during virus replication [2,3].
Despite great successes in the production and roll-out of vaccines against SARS-CoV-2, new variants are on the rise and there is still no globally accepted treatment for COVID-19 (https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1). During the last year, many laboratories focused on screening FDA-approved drugs for quick implementation in clinical settings [[4], [5], [6]]. A compound of interest from such work is the racemic mixture ivermectin, typically used to treat helminth infections. Most of the studies on the macrocyclic lactone ivermectin only consider the major constituent B1a in their dockings [7]. However, ivermectin is an approximately 80:20 mixture of two homolog derivatives of the compound avermectin B1, called 22,23-dihydro-avermectin B1a (HB1a) and B1b (HB1b) correspondingly, which differ in the presence of a sec-butyl and isopropyl group, at the C25 position, respectively (Fig. 1). Interestingly, this mixture has demonstrated in vitro antiviral activity against several single-stranded RNA viruses, such as Zika virus, dengue virus, Chikungunya virus, avian influenza A virus, Porcine Reproductive and Respiratory Syndrome virus, human immunodeficiency virus type 1, among others, including SARS-CoV-2 [8].




Comments